chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Bump on her lymph node. It is 5 inches long and 4 inches wide.; Vaccination site hot to touch; Redness; Bump on her clavicle; Vaccination site swelling; This spontaneous case was reported by a health care professional and describes the occurrence of LYMPHOEDEMA (Bump on her lymph node. It is 5 inches long and 4 inches wide.), VACCINATION SITE WARMTH (Vaccination site hot to touch), ERYTHEMA (Redness), SWELLING (Bump on her clavicle) and VACCINATION SITE SWELLING (Vaccination site swelling) in a 31-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 011Y20A and 007M20A) for COVID-19 vaccination.     No Medical History information was reported.   On 09-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 03-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 03-Feb-2021, the patient experienced LYMPHOEDEMA (Bump on her lymph node. It is 5 inches long and 4 inches wide.), VACCINATION SITE WARMTH (Vaccination site hot to touch), ERYTHEMA (Redness), SWELLING (Bump on her clavicle) and VACCINATION SITE SWELLING (Vaccination site swelling). The patient was treated with IBUPROFEN (IBUPROFEN EG) at a dose of unknown and PARACETAMOL (TYLENOL) at an unspecified dose and frequency. At the time of the report, LYMPHOEDEMA (Bump on her lymph node. It is 5 inches long and 4 inches wide.), VACCINATION SITE WARMTH (Vaccination site hot to touch), ERYTHEMA (Redness), SWELLING (Bump on her clavicle) and VACCINATION SITE SWELLING (Vaccination site swelling) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Treatment for the event included ibuprofen and acetaminophen.  Action taken with mRNA-1273 in response to the events was not applicable.
Came to location for Pfizer vaccine on 5/4/21.  She had a vasovagal reaction immediately after the vaccine.  Her B/P was 122/62.  She was pale and diaphoretic.  She was seen by Dr.  She recovered after a brief period and went home.
only mild muscle soreness at injection site; This is a spontaneous report received from a contactable nurse. A 56-year-old female patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: EC324U, expiry date: unknown), via an unspecified route of administration in the left arm, on 11Jan2021 (also reported as 21Jan2021, pending clarification), at single dose, for covid-19 immunization, at the hospital. Medical history included penicillin allergy. The patient was not pregnant at the time of vaccination. Concomitant medication included daily vitamins (other medications in two weeks). The patient did not receive other vaccines in four weeks. The patient did not have COVID-19 prior to vaccination and was not tested for COVID-19 post vaccination. On 11Jan2021, first dose, the patient only experienced mild muscle soreness at injection site. Treatment was not given for the event. The patient recovered from the event in Jan2021.
This is a spontaneous report from a contactable consumer via a Pfizer sales representative. A 20 year old female patient of an unspecified ethnicity received the first dose of TRUMENBA (batch number requested) via an unspecified route of administration on the arm on an unspecified date in 2017 at single dose as the patient was in the Group B recommendation for vaccine (immunization). The patient's medical history and concomitant medications were not reported. On an unspecified date in 2017 (reported as probably in the past 3 to 4 months), the patient received meningococcal group b rlp2086 and reported that her arm was sore and painful after the injection. The patient reported that the arm pain and soreness lasted a couple of days after the injection. The patient recovered from the events on an unspecified date in 2017. The following information on the batch number has been requested.
Pt received one dose of varicella virus vaccine live 2.5 weeks post exposure. Several days post vax, the pt developed very few pox marks. It was noted that the pt was afebrile. The pts sister had a similar experience following exposure to varicella virus vaccine live. Additional information has been requested.
I experienced an irregular menstruation cycle.  More painful and heavier than usual.  I'm currently mid cycle and so unable to determine if the cycles will normalize.
patient stated experienced "labored" breathing and he took himself to the ER. did not experience rash, itching, hives, swelling of mouth, lips, or throat. Pt is also experiencing severe nausea and headache.  Patient was instructed if continued to experience labored breathing to reach out to his primary care provider or seek medical attention.  Patient did not have any reaction to first dose in series.
Patient presented with huge red area around shot area. Sent her to E.R. and she was given an antibiotic. Not sure if infected by flu shot or just adverse effect. Her arm became sore and red shortly after receiving vaccine.
This spontaneous report was received from a registered nurse and refers to multiple patients of an unknown gender and age. The patients' concurrent conditions, medical history and concomitant therapy were not reported. On unknown dates, the patients were vaccinated with an unspecified number of doses of improperly stored VARIVAX (Merck) lot # L001335, expiration date: 13-JAN-2017 (dose and route of administration were not reported). There were no adverse effects reported. This is one of several reports received from the same reporter. Additional information has been requested.
Erythema, Pain, on medial left thigh, site of injection. Dtap site on left.
pt recv vax;cranky,crying;could not crawl/walk;exam nl;studies shows dec nerve conduction velocities lower extremities;dx polyneuropathy;felt to have polyradiculitis;MD suggest radiculopathy;could be secondary to viral process;listless;v;
This 4 year 5 month old female presentes for possible izzy reaction. Mother states that the pt has never previously had reactions to her immunizations. She says a red, hard bump developed on the pt's thigh over where she had her immunizations given on Wedneday that doubles in size overnight. Mother has not documented any fevers.
rash at injection site; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of injection site rash in a 75-year-old female patient who received Herpes zoster (Shingrix) (batch number Xy22f, expiry date 27-MAY-2024) for prophylaxis.   On 04-FEB-2023, the patient received the 1st dose of Shingrix (unknown arm). On 04-FEB-2023, 2 hrs after receiving Shingrix, the patient experienced injection site rash (Verbatim: rash at injection site). The outcome of the injection site rash was resolved (duration 6 hrs).   It was unknown if the reporter considered the injection site rash to be related to Shingrix.     It was unknown if the company considered the injection site rash to be related to Shingrix.   Additional Information: GSK Receipt Date:3-May-2023  The pharmacist reported that a patient developed a rash at their Shingrix injection site about 2 hrs after getting their first vaccine.  The patient reported that the rash resolved about 6 hrs afterwards. The reporter consented to follow up.
This spontaneous report was received from a Registered Nurse referring to a patient of unknown age and gender. The patient's medical history, concurrent conditions, concomitant medications, and historical drugs were not reported. On 21-NOV-2017, the patient inadvertently received both VARIVAX 0.5 ml subcutaneously (frequency, anatomical location were unknown) with lot # M015731 and expiration date 30-MAR-2018 and PROQUAD (route, dose, frequency, anatomical location were unknown) with lot # N002336 and expiration date 19-JUL-2018 for prophylaxis, both reconstituted with sterile diluent (MERCK STERILE DILUENT) with lot # L019488 and expiration date 11-FEB-2018.
This is a spontaneous report from a Pfizer sponsored program. A contactable physician reported for a 75-year-old female patient received PREVNAR 13, (lot number and expiration date were not reported), via an unspecified route of administration from an unspecified date at single dose for immunization. The patient's medical history and concomitant medications were not reported. On an unspecified date, it was reported that in the allergy section of the application on the medication list the following medication was noted to HCP: PREVNAR 13. Outcome of the event was unknown. Information on lot number, batch number and expiration date has been requested.
Information has been received from a physician concerning a over 60 year old female with a history of shingles who on approximately 20-MAY-2008 was vaccinated subcutaneously with a 0.65 ml dose of ZOSTAVAX (Merck). Subsequently, the patient experienced pain, hardness and swelling at injection site shortly {1-2 days} after receiving ZOSTAVAX (Merck). The latter events ceased after one week. However, the patient experienced pain in lower back about 1 week after receiving ZOSTAVAX (Merck). This was the same area where the patient developed shingles previously. The physician was requesting a culture kit to diagnose shingles. The patient's pain at injection site and in lower back persisted. Unspecified medical attention was sought by patient. Additional information has been requested.
Patient was 15 at the time of administration of the vaccine. Patient's mother intentionally listed his birthday incorrectly on vaccine forms to make it seem the patient was 16 years old. Patient's real birthday is 10/11/2005. Mother listed the birthday on all forms as 10/11/2004. While processing the vaccine, the insurance rejected the claim due to invalid birthday. I contacted the patient's pediatrician's office, who confirmed the birthday as 10/11/2005. I spoke with the mother on 4/26/21, who confirmed that she lied about the patient's birthday so he could get a dose of vaccine. I advised that the vaccine is only approved for 16 and over and we would be unable to administer the 2nd dose of vaccine. I contacted the pediatrician's office on 4/27/21 to inform them of the incident.
Patient having sore throat, fatigue, abdominal pain, decreased appetite, fever for last 2 weeks onset on 4/7/11. Pt was given amoxicillin due to possible thought of infection. Pt developed thrush x 2 days after starting abx. Pt symptoms no improved with antibiotic. Pt family has history of having reactions to various vaccinations. Reactions to this vaccination rare but do include decreased appetite, fever, and abd. pain. Fever of 102.2 comes & goes.
Patient developed swelling to eyelid approximately 15 minutes after injection. Developed voice hoarseness and salivating about 1 hour after vaccine
Swollen lymph nodes began immediately after vaccination and a growth in left breast became palpable in August 2021
Headache everyday for 3 days upon waking up. Typically around 8:45am
Left arm was sore after the first dose; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Left arm was sore after the first dose) in a 71-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Seasonal allergy.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PAIN IN EXTREMITY (Left arm was sore after the first dose). At the time of the report, PAIN IN EXTREMITY (Left arm was sore after the first dose) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were reported. Treatment included Tylenol and Claritin   This case was linked to MOD-2021-032604.
symptom onset 05/25- cough , SOB, headache, poor appetite, abdominal discomfort.
Headache; Pain Injection Site Left Arm; This spontaneous case was reported by a consumer and describes the occurrence of   in a 66-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 023M20A) for COVID-19 vaccination.     The patient's past medical history included No adverse event (No medical history reported.).    On 16-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 09-Feb-2021, Antibody test: Patient mentioned she has antibodies..     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
This spontaneous report as received from a 25 years old female consumer reporting on herself with no pertinent medical history, drug reactions or allergies. The patient was vaccinated with dose 1 of GARDASIL (lot #, dose and route not reported) sometime in February 2012 and the last dose of GARDASIL (lot #, dose and route not reported) was given 2 weeks late according to the recommended schedule in August 2012. No other co-suspects were reported. Concomitant medications included: ORTHO TRI-CYCLEN LO. The patient stated that she had begun losing hair since having the vaccination. Her hair loss began approximately in June 2012 and had gotten progressively worse  through August. At the time of the report she was still losing hair. The patient explained that the hair loss had not occurred in patches, but in overall thinning. She also stated that she had developed pain in her legs to the point of needing daily massages. The patient sought unspecified medical attention, no lab diagnostic tests were performed and no treatment was given for the events. The relatedness for the events was not provided for GARDASIL. Additional information is not expected.
doses were given after expiration date; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (doses were given after expiration date) in a 35-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 043B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 07-Oct-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 07-Oct-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (doses were given after expiration date). At the time of the report, EXPIRED PRODUCT ADMINISTERED (doses were given after expiration date) outcome was unknown. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported. No treatment medications were reported. The vial was initially refrigerated on 21 Sep 2021, the vial did not undergo any temperature excursion and patient did not experienced any adverse events.
Pt vaccinated with TD/MMR developed a rash & hives all over body following immunization. She was seen by the  MD & dx as having allergic event.
A non-serious spontaneous report of H1N1 LAIV inadvertently administered to 56-year old was received from a health professional concerning a female patient. The patient's medical history was not provided. On 25-Nov-2009, the patient received H1N1, Intranasal. There was no adverse event associated with this medication error; therefore, treatment and reporter causality assessments are not applicable, and the event was considered resolved.
This spontaneous report was received from a nurse refers to a 4 year old patient of unknown gender. No concurrent medication, medical history or allergy/drug reactions were reported. On 22-JUL-2015, the patient was vaccinated with improperly stored (Oka/Merck) VARIVAX (lot # K016129, exp date: 25-SEP-2016) (dose, strength, route and frequency were not reported). No concomitant medications were reported. No adverse effects were reported. The outcome of the event was unknown. There were no product quality complaints (PQC) involved. No further information was provided. This is one of several reports received from the same reporter. Additional information has been requested.
Information has been received from a nurse referring to multiple unspecified patients (age and gender were not reported). On unspecified dates, the patients were vaccinated with doses of PNEUMOVAX 23 (dose, dose #, route and application site were not reported). The injection of PNEUMOVAX 23 was painful for those patients. Outcome of the adverse event was unknown. The relatedness between painful injection and PNEUMOVAX 23 was not provided. Additional information has been requested.
Per MD, "rash is probably due to MMR immunizations", under eyes, toes, legs and belly. Temperature 101F on 8/20/01. Ankle swelling and pain with a limp
Nausea; Vomiting; Headache; Chills; This spontaneous case was reported by a consumer and describes the occurrence of NAUSEA (Nausea), VOMITING (Vomiting), HEADACHE (Headache) and CHILLS (Chills) in a 69-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030B21A) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included AMFETAMINE ASPARTATE, AMFETAMINE SULFATE, DEXAMFETAMINE SACCHARATE, DEXAMFETAMINE SULFATE (ADDERALL), ARIPIPRAZOLE, BUSPIRONE HYDROCHLORIDE (BUSPAR) and SERTRALINE HYDROCHLORIDE (ZOLOFT) for an unknown indication.    On 29-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 29-Apr-2021, the patient experienced NAUSEA (Nausea), VOMITING (Vomiting), HEADACHE (Headache) and CHILLS (Chills). The patient was treated with IBUPROFEN at a dose of 1 dosage form; PARACETAMOL (TYLENOL) at a dose of 1 dosage form and BISMUTH SUBSALICYLATE, CALCIUM CARBONATE (PEPTO BISMOL [BISMUTH SUBSALICYLATE;CALCIUM CARBONATE]) at a dose of 1 dosage form. On 30-Apr-2021, NAUSEA (Nausea), VOMITING (Vomiting), HEADACHE (Headache) and CHILLS (Chills) had resolved. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.
Client was asked his age and he stated he was 12 years old. The administering nurse asked another nurse the age of the client and it was stated 12 years old.  The administering nurse realized after the injection that the client will turn 12 years old in 3 months. No adverse reactions client monitored x 30 minutes. Parent informed.
Flu-like symptoms the entire next day. Achy joints, muscle pain, fatigue.
This spontaneous report as received from a Licensed Practical Nurse, who reported that on 02-AUG-2013, two patients of unknown age and gender received a dose of GARDASIL (lot # J004197, expiration date 27-NOV-2015) (dose and route were not reported) exposed to 31F for 84 hours over the past two months, since approximately June 2013. Concomitant medications were not reported. No adverse effects reported. This case is linked to cases 1308USA010552, 1309USA004737, 1309USA004746, and 1309USA004747 via same reported link. Follow up information as received from a Licensed Practical Nurse refers to a 13 year old patient received a dose of GARDASIL (lot # J004197, expiration date 27-NOV-2015) (dose, location and route were not reported) exposed to 31F for 84 hours over the past two months, since approximately June 2013. Concomitant medications were not reported. No adverse effects reported. This is one of several reports received from the same reporter. Additional information has been requested.
Right arm sore. Flu-like symptoms for a day: chills, aches, headache. Aches persisting into 2nd day.
Patient left the pharmacy pushing shopping cart after I administered flublok in left arm. He returned to the pharmacy 10 minutes later and sat down. When I went to talk to him he was slightly disoriented and confused and said he was unable to lift his right arm to pick something up while he was shopping and thought he should come sit down at the pharmacy. No swelling or redness on the immunization arm, blood pressure and pulse were normal for patient. He wouldn't let me call 911 but he did let me call his son. His son picked him up and took him to the ER and he was later diagnosed with mild stroke and issues related to the battery on his pacemaker not working.  It is unknown if the flu shot had anything to do with the stroke or if it was just coincidence.
This spontaneous report as received from a pharmacist refers to a 52 year old female patient. There were no known drug reactions reported. On 04-DEC-2013 the patient was vaccinated with ZOSTAVAX subcutaneous (strength not reported, lot # J011211, dose: 0.65 ml in the right arm). Other suspect therapies included influenza virus vaccine (manufacturer unknown) (also injected in the right arm). On 04-DEC-2013 the patient reported that ZOSTAVAX vaccination site was red, swollen and warm to touch. No treatment was given. No lab diagnostics studies were performed. The patient did not seek medical attention. The outcome of events was reported as not recovered/not resolved. The relatedness between ZOSTAVAX and influenza virus vaccine (manufacturer unknown) and events was not reported. Additional information has been requested.
Patient complained of body heat.  1:10pm Patient refused to take B/P.  Stated she is feeling better.  EMS informed patient if symptoms return to call 911 or primary care doctor. (Patient is alertx3).  Verbalized understanding.
Td administration on 10/10/2003.  Noticed rash 10/12/2003 with itchy.  Getting progressively worse.
Parkinson like tremors in left arm/hand and left thigh (possible stroke or Parkinsons).  Also, diagnosed with Diabetes blood sugar level.
This spontaneous report as received from a healthcare worker refers to a 13 year old patient of unknown gender. There was no information about the patient's concomitant medications and pertinent medical history reported. On 02-JUL-2015, the patient was vaccinated with an improperly stored dose of GARDASIL (lot# K023432, expiration date 18-JUN-2016) (strength, dose, route and site of administration were not provided). No adverse effects were reported. This is one of several reports from the same reporter. Additional information has been requested.
This is a spontaneous report from a contactable consumer (patient). A patient of unspecified age and gender received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection; Batch/Lot number and Expiration Date: not reported), via an unspecified route of administration on an unspecified date as unknown, single for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. On an unspecified date, the patient experienced a little back pain in the right side, it continued to the hip, it could be just my back (as reported). The patient's back was hurting, he cannot walk too quickly. It was further reported that the patient was not feeling any fever nor anything like that. The patient was told to take only paracetamol (TYLENOL) but the patient was wondering, if it was okay to take anything else at this point since it was on Monday (as reported) that the patient had the vaccine. The patient have a back pain at the time of the report and didn't think it was really vaccine related, it could be the patient's own issue. The patient was asking if something can be taken other than paracetamol. Outcome of all events was not recovered. No follow-up attempts are needed; information about lot/batch number cannot be obtained.